Quantcast

Industry news that matters to you.  Learn more

Archives for June 2012

Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine

Gentris Corporation, a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine. The goal of this USA-China collaboration is to create translational research and epidemiological projects, as well as training and education programs, focused on pharmacogenomics and clinical sample banking, which will drive innovation in drug development and improvements in patient care.

Definiens Expands Large Data Analytics Functionality to Accelerate Image-based Research and Development

Definiens, the leading provider of image analysis and data mining solutions for quantitative digital pathology, today announced the release of Definiens Image Miner 2. The new product provides researchers in the life sciences with deeper insights into underlying biology by integrating image with data analysis. Image Miner 2 makes the wealth of information in biomedical images accessible, accelerating life sciences research and allowing for successful biomarker development.

Aushon Launches Cira Multiplex Protein Biomarker Platform

Aushon announced the launch of Cira, a new multiplex immunoassay platform that achieves the sensitivity and reproducibility of singleplex ELISA, while substantially improving ease of use and leveraging the benefits of parallel analysis. The system’s revolutionary design produces faster results at a lower cost per sample and higher throughput without compromising the quality or consistency scientists need for their clinical studies.

bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer

bioTheranostics, Inc., provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that its PRÉCISSM Precision Medicine biomarker profiles for non-small cell lung and cancers have been expanded. The profiles now include 13 non-small cell lung and seven colorectal cancer clinically relevant tumor biomarkers, many of which also may be used in other cancers such as melanoma.

Epigenomics AG Announces Non-exclusive Licensing Agreement for Septin9 with Companion Dx Reference Lab

Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin9 with Companion Dx Reference Lab (“Companion Dx”), an emerging leader in pharmacogenomic testing and cancer companion diagnostics. Under the terms of the agreement, Companion Dx has obtained rights to establish and commercialize a blood-based, laboratory-developed test (LDT) using methylated Septin9 as biomarker for the detection of colorectal cancer. Epigenomics is entitled to double digit royalties on sales.

“The addition of Septin9 to our offering of cancer related products will allow us to more effectively serve the Texas cancer testing market. Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., and we believe that the blood based method to detect colorectal cancer in the currently non-compliant patient population will improve participation in screening and therefore save more lives in Texas”, said Steve Blum, CEO of Companion Dx.

“Based on the growing uptake of the Septin9 assay through our LDT licensees, we are excited to add regionally focused Companion Dx lab to the list of our partners as we recognize their ability to reach incremental sub-populations who should be but are not currently screened according to guidelines”, said Noel Doheny, Chief Executive Officer of Epigenomics’ US subsidiary. “Companion Dx shares our objective of providing tests that will help physicians to improve the health outcomes for patients through accurate detection of colorectal cancer and to potentially decrease the rising costs associated with colorectal cancer in the U.S. With today’s licensing agreement, we continue to execute on our commercialization strategy, well ahead of the launch of a proprietary diagnostic product approved by the FDA”, explained Mr. Doheny.

The agreement with Companion Dx complements Epigenomics’ LDT agreements with Quest Diagnostics, ARUP Laboratories and Warnex Medical Laboratories in North America. Furthermore, Abbott Molecular has worldwide, non-exclusive license to develop and to commercialize IVD test kit products while Qiagen and Sysmex have acquired options to do so.

Source: